Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data
Pendleton N; Casanueva FF; Huhtaniemi IT; Lunt M; Han TS; Ahern T; O'Neill TW; Vanderschueren D; Wu FCW; Slowikowska-Hilczer J; Rutter MK; Lean MEJ; Swiecicka A; Bartfai G; Giwercman A; Forti G; Punab M
Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data
Pendleton N
Casanueva FF
Huhtaniemi IT
Lunt M
Han TS
Ahern T
O'Neill TW
Vanderschueren D
Wu FCW
Slowikowska-Hilczer J
Rutter MK
Lean MEJ
Swiecicka A
Bartfai G
Giwercman A
Forti G
Punab M
OXFORD UNIV PRESS INC
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042717133
https://urn.fi/URN:NBN:fi-fe2021042717133
Tiivistelmä
Context: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evidence is conflicting and prospective data are largely lacking.Objective: To determine associations between nonandrogenic anabolic hormones and prospective changes in frailty status.Design/Setting: A 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study.Participants: Men (n = 3369) aged 40 to 79 years from eight European centers.Main Outcome Measures: Frailty status was determined using frailty phenotype (FP; n = 2114) and frailty index (FI; n = 2444).Analysis: Regression models assessed relationships between baseline levels of insulinlike growth factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status (worsening or improving frailty).Results: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3, and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI, -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), -4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP only in men >70 years old [OR, 0.57 (0.35, 0.92)]. PTH was unrelated to change in frailty status.Conclusions: These longitudinal data confirm the associations between nonandrogenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.
Kokoelmat
- Rinnakkaistallenteet [19207]